Neuronetics announced the publication of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in the field of neuromodulation. This analysis concludes that while early symptom improvement in major depressive disorder is strongly predictive of response at the completion of transcranial magnetic stimulation treatment, lack of early improvement does not predict final treatment outcome. “These findings provide hope for practitioners and patients alike that a lack of improvement early in a TMS treatment regimen does not predict final non-response status, reinforcing the importance of completing the full prescribed treatment course for maximum results,” said Cory Anderson, Senior Vice President of Research & Development and Clinical, Neuronetics. “Insurers, practitioners, and patients can all take note that patients who are slow to respond to the treatment process still have a significant likelihood of improving by the end of their full course. This paper builds upon prior publications utilizing data from our proprietary TrakStar database, which showed a correlation between treatment sessions completed and positive clinical outcomes. Treating to completion of 36 NeuroStar sessions offers patients the greatest potential to benefit from NeuroStar TMS treatment.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- Neuronetics Inc Shrinks Board Following Strategy Review
- Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- NeuroStar Advanced Therapy receives FDA clearance
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression